BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres†

Br J Haematol. 2021 Feb;192(3):e94-e98. doi: 10.1111/bjh.17279. Epub 2021 Jan 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / therapeutic use*
  • Cytarabine / therapeutic use*
  • Etoposide / therapeutic use*
  • Humans
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / therapy
  • Melphalan / therapeutic use*
  • Prospective Studies
  • Stem Cell Transplantation
  • Transplantation, Autologous

Substances

  • Cytarabine
  • Etoposide
  • Bendamustine Hydrochloride
  • Melphalan